Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Cognitive tests and assessment

Topic: Brain proteins, microglia and lab models

Plain-language summary

Data collection began in March 2024. So far 562 people completed a pre-screening online questionnaire, with 190 passing pre-screening of whom 54% met eligibility criteria. Of the 73 participants who were screened face-to-face so far, 33% (N = 24) were eligible. Of those deemed ineligible, 44% did not meet criteria for MCI, 44% did not meet criteria of MetS, and 12% did not want to participate. Nineteen participants were randomized, 2 dropped out before beginning treatment and 5 are awaiting randomization. Randomized participants have an average age of 66.7 years [SD=5.26], BMI of 32.8 [SD=5.7], MMSE of 25.0 [SD=2.6] and Hba1c of 5.6 [SD=0.31]; 61% are women. This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial investigating the cognitive benefits of the combination of INI and oral semaglutide in individuals with MetS and at high dementia risk. This combination targets multiple pathways implicated in cognitive decline, potentially offering a novel therapeutic approach for the understudied yet highly prevalent and high-risk MetS population.

What this study adds

Evidence grade: High

The record lists 24 participants. This is a feasibility study still collecting data, with only 19 participants randomized so far, testing a combination of intranasal insulin and oral semaglutide in older adults with metabolic syndrome at high dementia risk. No cognitive results are reported yet, so it cannot show whether the combination helps thinking or prevents dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Shamrok, H., Davidy, T., Yore, I., Niv, T., Yaffe, T. C., Ravona‐Springer, R., et al. (2025). Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk. Alzheimer s & Dementia. https://doi.org/10.1002/alz70860_102127

Vancouver

Shamrok H, Davidy T, Yore I, Niv T, Yaffe TC, Ravona‐Springer R, et al. Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk. Alzheimer s & Dementia. 2025. doi:10.1002/alz70860_102127. PMID: 41434629.

BibTeX

@article{shamrok2025-41434629,
  author  = {Shamrok, Hanadi and Davidy, Tal and Yore, Iscka and Niv, Tal and Yaffe, Tali C and Ravona‐Springer, Ramit and Livny, Abigail and Lesman‐Segev, Orit H. and others},
  title   = {{Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70860_102127},
  pmid    = {41434629},
  url     = {https://doi.org/10.1002/alz70860_102127}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This is a feasibility study still collecting data, with only 19 participants randomized so far, testing a combination of intranasal insulin and oral semaglutide in older adults with metabolic syndrome at high dementia risk. No cognitive results are reported yet, so it cannot show whether the combination helps thinking or prevents dementia.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 45 of 100.45 of 100 points earned55 not earned

Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 24 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Michal Schnaider Beeri: h-index 52 (OpenAlex, whole career)
Institution's track record 1 / 3 Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41434629)
Free to read 2 / 2 Free to read
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →